Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects
- 25 November 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 116 (22) , 4700-4702
- https://doi.org/10.1182/blood-2010-06-289991
Abstract
Adoptive transfer of viral antigen-specific memory T cells can reconstitute antiviral immunity, but in a recent report a majority of virus-specific cytotoxic T-lymphocyte (CTL) lines showed in vitro cross-reactivity against allo-human leukocyte antigen (HLA) molecules as measured by interferon-γ secretion. We therefore reviewed our clinical experience with adoptive transfer of allogeneic hematopoietic stem cell transplantation donor-derived virus-specific CTLs in 153 recipients, including 73 instances where there was an HLA mismatch. There was no de novo acute graft-versus-host disease after infusion, and incidence of graft-versus-host disease reactivation was low and not significantly different in recipients of matched or mismatched CTL. However, we found that virus-specific T cell lines recognized up to 10% of a panel of 44 HLA disparate targets, indicating that virus-specific T cells can have cross-reactivity with HLA-mismatched targets in vitro. These data indicate that the adoptive transfer of partially HLA-mismatched virus-specific CTL is safe despite in vitro recognition of recipient HLA molecules.Keywords
This publication has 16 references indexed in Scilit:
- Allo-HLA reactivity of virus-specific memory T cells is commonBlood, 2010
- Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplantsImmunologic Research, 2007
- Preemptive Therapy of EBV-Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell TransplantationAmerican Journal of Transplantation, 2007
- Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponseBlood, 2006
- Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individualsNature Medicine, 2006
- Robust Expansion of Viral Antigen-specific CD4+ and CD8+ T Cells for Adoptive T Cell Therapy Using Gene-modified Activated T Cells as Antigen Presenting CellsJournal of Immunotherapy, 2006
- Transfer of allogeneic CD62L– memory T cells without graft-versus-host diseaseBlood, 2004
- Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell linesThe Lancet, 2003
- Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the DonorNew England Journal of Medicine, 1995
- Production of Genetically Modified Epstein-Barr Virus-Specific Cytotoxic T Cells for Adoptive Transfer to Patients at High Risk of EBV-Associated Lymphoproliferative DiseaseJournal of Hematotherapy, 1995